Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›CSOP›03174

03174

CSOP Hang Seng Biotech ETF

Passive ETF Equity

Not rated

The 03174 Exchange Traded Fund (ETF) is provided by CSOP. It is built to track an index: Hang Seng Biotech Index. The 03174 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

HK$3.42

N/A

Data as of 08/05/26

1D price range

N/A

52W price range

HK$2.84HK$4.40

YTD Perf.

+0.51%

YTD Flows

Annualized volatility

Fund AuM

€96M

Share class AuM

€96M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

HK0000756202

TER

0.99%

Inception date

7/20/2021

Issuer

CSOP

Benchmark

Hang Seng Biotech Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
83069 ChinaAMC Hang Seng Biotech ETF	+0.42%

API

PerformanceDec 31, 2025 - Aug 5, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

96.49%

Consumer Non-Cyclicals

3.28%

Unavailable

0.23%

Latest 03174 news

No content available for this fund

FAQ about 03174

03174 is a Passive ETF. This ETF provides exposure to Biotechnology Equities.

03174 tracks the Hang Seng Biotech Index - HKD, through a optimized sampling replication method.

03174 carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.

03174 was introduced to the market on July 20, 2021. It trades on Hong Kong

CSOP Hang Seng Biotech ETF, 03174, is provided by CSOP. Learn more about CSOP here.

03174 oversees €96M in assets as of August 5, 2026.

03174 follows a distributing dividend policy, meaning it pays out income to investors.

As of June 30, 2026, 03174 has significant geographic allocations in China, Hong Kong and Switzerland.

As of June 30, 2026, 03174 focuses largely on Healthcare and Consumer Non-Cyclicals.

As of June 30, 2026, 03174 holds 30 positions in its portfolio, with 83.09% of assets concentrated in its top 15 holdings.

As of June 30, 2026, 03174 top three holdings include Innovent Biologics, Inc., BeOne Medicines Ltd. and WuXi Biologics (Cayman), Inc..

The base currency of 03174 is HKD.

Top 10 holdings

Data as of 06/30/26

Innovent Biologics, Inc.

10.42%

BeOne Medicines Ltd.

10.42%

WuXi Biologics (Cayman), Inc.

10.16%

WuXi AppTec Co., Ltd.

8.63%

Akeso, Inc.

7.51%

CSPC Pharmaceutical Group Ltd.

6.51%

Sino Biopharmaceutical Ltd.

5.27%

Hansoh Pharmaceutical Group Co., Ltd.

5.19%

3SBio, Inc.

3.96%

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

3.28%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

CSOP Hang Seng Biotech ETF

FAQ about 03174

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US